newest glp 1 agonist GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Comparing Ozempic, Wegovy and Other

Biological actions of GLP-1, source: reference [1] Evolution of GLP1 GLP-1RAs Currently, there are nine GLP-1RAs approved for marketing worldwide (Table 1), mainly for the treatment of diabetes and obesity, of which tirzepatide is a novel dual GLP-1RA/GIPR agonist

TRIUMPH-4 has already delivered positive topline results

However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors

Participants treated with liraglutide (239), semaglutide (240), or tirzepatide (200) in the clinical trials had a percent reduction in fat mass approximately three times greater than the reduction in lean mass, leading to an overall improvement in body composition

K.HernandezA

Willow did not respond to requests seeking comment about its marketing